Clinical studies in schizophrenia patients have shown that adding a selective serotonin reuptake inhibitor (SSRI) to antipsychotics can ameliorate negative symptoms that frequently resist standard treatments. It has been proposed that this combined treatment produces a 'net effect', different from that of the individual drugs and possibly common to that of the atypical antipsychotic, clozapine, which also ameliorates negative symptoms. The present study was initiated to determine the molecular events in the rat frontal cortex resulting from combined treatment of fluvoxamine and haloperidol compared to clozapine. Rats were allocated to five groups and received a daily intraperitoneal injection with one of the following : haloperidol (1 mg/kg), fluvoxamine (11 mg/kg), clozapine (11 mg/kg), haloperidol (1 mg/kg) plus fluvoxamine (11 mg/kg), or vehicle for 30 d. cDNA arrays were used to screen a broad range of genes in the frontal cortex. Several of the most prominent alterations were taken for analysis in real-time RT-PCR and their related proteins were examined by the Western-blotting technique. The gene expression profile of the combined fluvoxamine plus haloperidol treatment was different from that of the individual drugs. Moreover, clozapine showed some degree of homology with the dual treatment. The protein expression changes, specific to the combined treatment, included glutamic acid decarboxylase (GAD67) and protein kinase Cb (PKCb). The latter showed a similar trend following clozapine treatment. The present findings support the existence of a unique mechanism for SSRI-antipsychotic combination, different from that of the individual drugs and suggest that it may involve modification of the gamma aminobutyric acid (GABA) system.
Introduction
Negative symptoms of schizophrenia such as apathy, loss of emotional response, and social withdrawal respond poorly to antipsychotic treatment. Recent studies reported that adding a selective serotonin reuptake inhibitor (SSRI) such as fluvoxamine Silver and Nassar, 1992 ; Silver and Shmugliakov, 1998 ; Yasui-Furukori et al., 2004) or fluoxetine (Goff and Evins, 1998) to typical antipsychotics can improve negative symptoms in patients who did not respond to antipsychotics alone. The improvement included key negative symptoms primary to the illness (Silver et al., 2003a) and could be detected as early as 2 wk after treatment onset (Silver et al., 2003c) . Since maprotiline, an antidepressant acting by a noradrenergic mechanism was not effective compared to fluvoxamine, amelioration of negative symptoms appears to be related to the serotonergic action rather than to a non-specific antidepressant effect of the drug (Silver and Shmugliakov, 1998) .
The mechanism underlying the therapeutic action of the combined treatment is unknown. Based on the clinical observation that the outcome of the combined treatment is different from the individual drugs it is reasonable to expect a parallel effect at the molecular level. Indeed, a recent study has shown that combined administration of olanzapine and fluoxetine results in behaviour, endocrine and immediate-early gene expression changes unpredicted by monotherapy models (Horowitz et al., 2003) . In light of the reported abnormalities in dopamine, serotonin, c-aminobutyric acid (GABA) and glutamate systems in schizophrenia (Carlsson et al., 2001 ; Ichikawa and Meltzer, 1999 ; Wassef et al., 2003 ; Yan, 2002) , we believe that alteration of the dynamic interaction between these systems might distinguish the ' net effect ' of the combined treatment from the individual drugs.
In a search for molecular alterations that may be related to the clinical outcomes, we studied the effects of chronic co-administration of haloperidol with fluvoxamine in rat brain and compared it to the action of each drug alone and to the action of clozapine, considered as the 'gold standard ' in respect to the activity against negative symptoms. The frontal cortex was chosen for this study since frontal lobe abnormalities have been linked to negative symptoms in schizophrenia patients and because it is postulated to be a central site for the action of antipsychotic drugs. To enable coverage of a broad range of signalling systems we used microarray as a screening tool and subsequently focused on genes of interest using realtime RT-PCR and Western blotting.
Methods

Animal protocol
All procedures were in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the Technion Animal Ethics Committee, Haifa, Israel. Male Sprague-Dawley rats (Harlan, Jerusalem, Israel), weighing 150-250 g at the beginning of experiments, were housed for an acclimatization period of 1 wk before starting the experiment. Rats were randomly assigned to five treatment groups (six rats per group), which received daily intraperitoneal (i.p.) injections (between 10 : 00 and 13 : 00 hours) of haloperidol (Sigma, St. Louis, MO, USA, 1 mg/kg), fluvoxamine (Agis, Tel Aviv, Israel, 11 mg/kg), a solution combining both haloperidol and fluvoxamine (1 mg/kg and 11 mg/kg respectively), clozapine (Novartis Pharmaceuticals Inc., Basle, Switzerland, 11 mg/kg) and vehicle [sterile saline solution containing 2 % dimethylsulphoxide (DMSO) and 70 mM acetic acid, control group]. The doses of the drugs are in accordance with the literature (Adams and Moghaddam, 2001 ; Bai et al., 2003 ; Chong et al., 2002 ; Daniel et al., 1999 ; Gao et al., 1997 ; Silver and Youdim, 2000) . The drugs were dissolved in a sterile saline solution containing 2 % DMSO and 70 mM acetic acid. In order to minimize tissue damage, the site of i.p. injection was varied between right and left side of the rat during the period of treatment. Mild and transient tissue injury was noted in some animals. During the treatment period animals were weighed once a week prior to drug administration. Baseline body weights were not significantly different except for the clozapine group which was significantly smaller [mean weight of 18-21 rats (¡S.E.M.) : vehicle 216¡6 g, haloperidol 218¡6 g, fluvoxamine 217¡8 g, haloperidol plus fluvoxamine 215¡9 g, clozapine 191¡3 g (clozapine vs. vehicle, p<0.01). The percentage weight gain during the study did not differ significantly between groups (saline 44 %, haloperidol 44 %, fluvoxamine 45 %, haloperidol plus fluvoxamine 45 %, clozapine 52 %). On day 31, 24 h after the last injection, the rats were sacrificed by decapitation. The brains were rapidly removed and dissected for the frontal cortices (olfactory bulbs were removed and a coronal cut was done 2.5 mm from the forehead, for tissue section between Bregma 5.2 and Bregma 2.7). From each brain the right-side organ was inserted immediately into RNAlater TM (Ambion, Austin, TX, USA) solution and was kept at x20 xC. The left side of the organ was frozen immediately for protein analysis.
Drug level determination
Initially we assayed blood samples from study animals (i.e. 24 h after the last dose). This resulted in undetectable levels in the blood. We then conducted an equivalent experiment but sacrificed animals 1.5 h after the last dose. These values are reported here. The levels of fluvoxamine and clozapine were analysed using HPLC with oxaprotiline or fluperlapine respectively as internal standards (Hartter et al., 1992 ; Weigmann et al., 2001 ). The level of haloperidol was determined using a liquid chromatography (LC) system coupled with mass spectrometry in the laboratory of Professor Zernig at Innsbruck, Germany.
Total RNA isolation
The frontal cortex tissues were transferred from RNAlater (x20 xC) into cold TriReagent solution (Sigma) and homogenized in a glass Teflon homogenizer. The TriReagent suspensions were mixed thoroughly with chloroform and centrifuged (12 000 g, 20 min, 4 xC). After precipitation with sodium acetate (0.3 M) and isopropanol, the RNA pellet was washed twice with 70 % ethyl alcohol (7500 g, 10 min), followed by one wash with 100 % ethyl alcohol (12 000 g, 10 min), resuspended in diethylpyrocarbonate (DEPC)-treated water and incubated for 5 min at 56 xC to facilitate resuspension. Total RNA aqueous solution was treated with DNase/RNase free (Roche Diagnostics, Mannheim, Germany) for 30 min at 37 xC and subsequently was extracted by a round of phenol : chloroform : isoamylalcohol (25 : 24 : 1) followed by a round of chloroform. After precipitation with sodium acetate (0.3 M) and isopropanol, the RNA pellet was washed as described above with 70 % and 100 % ethyl alcohol and resuspended in DEPC-treated water. RNA sample concentrations were determined by UV spectrophotometry at 260 nm. The quality of RNA was assessed by the absorbance at the 260/280 nm ratio and by denaturating gel analysis through direct visualization of 18S and 28S rRNA bands.
Atlas cDNA arrays
Hybridization array analysis was performed using Atlas Rat 1.2 cDNA expression arrays, including 1176 genes, according to the manufacturer's protocol (Clontech, Palo Alto, CA, USA). Probes were generated from RNA pools and analysed on cDNA arrays. Two independent experiments were performed. The membranes were exposed to phosphor screen (BAS MP-2040 image plate, Fuji Inc., Tokyo, Japan) and the radioactive signals were detected with FLA-2000 scanner (Fuji Inc.) . Quantification and analysis of the radioactive signals were done using AtlasImage TM 2.01 software (Clontech). The analysis was done by taking the log 2 of the ratio for the expressed genes and calculating their mean and standard deviation. Global normalization was done based on the assumption that all of the genes in the array should have an average expression ratio equal to 1 and that the changes in expression of the individual genes balance out so that the total quantity of RNA hybridized from each sample is the same (Quackenbush, 2001) . Changes with log 2 ratio greater than 2 S.D. of the mean were considered as significant (Kontkanen et al., 2002 ; Nadon and Shoemaker, 2002) .
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR)
The RNA prepared for microarray analysis was used for the real-time RT-PCR analysis of genes of interest. Two micrograms of total RNA were denatured and reverse transcribed using random hexanucleotides (0.5 mg/ml). Secondary structures of the template and primer were opened by incubation for 5 min at 70 xC and immediately cooled on ice. A total of 9 ml of mixed reaction containing reaction buffer, dNTP (0.5 mm each), RNasin inhibitor (25 U) and MMLV reverse transcriptase (200 U) were added and samples were incubated at 39 xC for 1 h. For every RNA preparation, a negative control was run in parallel consisting of a direct amplification of the RNA sample, omitting the RT step. Real-time quantitative assessment was performed using LightCycler with FastStart DNA Master SYBR Green I ready-to-use PCR mix kits according to the manufacture's protocol (Roche Diagnostics, Mannheim, Germany). The sequences of the primers are described in Table 1 . The results were analysed in real time on the provided program of LightCycler. Normalizing to the housekeeping gene 18S-rRNA and comparing to control values assessed the relative expression level of a given mRNA. Amplified products were visualized on 1.5 % agarose gel. In addition, the specificity of the PCR product was verified by sequencing using the primers that were used for cDNA amplification.
Protein determination and Western blotting
Brain tissue lysates were prepared by tissues homogenization in Tris-sucrose buffer (pH 7.4) (containing a mixture of protease inhibitors ; Roche Inc.) and centrifugation at 500 g for 10 min. The supernatants 
All templates are initially denatured for 10 min at 95 xC. Amplification is done for 35 cycles. In order to receive melting temperatures of the products (200 bp), melting-curve analysis is done by continues acquisition from 65 xC to 95 xC with temperature transition rate of 0.1 xC/s.
were assessed for the amount of protein using Bradford reagent (Sigma) at 598 nm. Samples containing 30 mg protein were loaded on a NuPAGE 10 % gel (Invitrogen, Groningen, The Netherlands). At the end of the electrophoresis, the proteins were transferred to a nitrocellulose membrane using an Xcell SureLock 1 apparatus (Invitrogen). The membrane was blocked with 5 % milk and immunoblotted with primary antibody and subsequently with a second, horseradish peroxidase-conjugated antibody [polyclonal anti-rabbit IgG conjugated with horseradish peroxidase (Cell Signaling Technology, Beverly, MA, USA) or anti-mouse IgG peroxidase conjugate (Sigma)]. Bands were revealed by enhanced chemiluminesence using the detection reagent, ECL (Amersham, Pharmacia, Little Chalfont, Buckinghamshire, UK). Quantification of results was accomplished by measuring the optical density of the labelled bands from the autoradiograms, using the computerized imaging program ' Total-lab ' (BioSystematica, Tavistock, Devon, UK). The following antibodies were used : affinity-purified rat anti-rat cyclin D3, mouse anti-human Presenilin1, Goat anti-human GABA-A receptor subunit b3 (GABA-A Rb3) and regulator of G protein signalling (RGS4 ; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), mouse anti-rat glutamate decarboxylase (GAD67), mouse anti-human protein kinase Cb and Cc (PKCb and PKCc ; Transduction Laboratories, Lexington, KY, USA), rabbit anti-mouse bcl-2-associated death promoter (BAD, Cell Signaling Technology Inc.), monoclonal anti-b-actin (clone AC-15) (Sigma).
Statistical analysis
All results were analysed using one-way ANOVA followed by Student's t test. A change was defined as being significant if the difference between the control and treated groups reached a level of significance of p<0.05.
Results
Drug level determination
The drug level in the rat brain tissues are presented in Table 2 and are in agreement with the literature (Baldessarini et al., 1993 ; Bymaster et al., 2002 ; Igarashi et al., 1995 ; Zhang et al., 2000) . The levels of haloperidol as well as of fluvoxamine are of the same order when given in separated or combined regimens.
Preliminary screening of the mRNA alterations using cDNA arrays cDNA array was used to generate a list of candidate genes of interest for further study. This method, despite its well-known limitation in quantification of mRNA levels, was employed as a preliminary screening tool to detect plausible related genes without a narrowed a-priori hypothesis. The final list consisted of expressed genes that showed changes greater than 2 S.D. of the average ratio (Table 3) . From the genes altered, eight were chosen for further corroboration by real-time PCR (Cyclin D3, PKCc, PKCb, BAD, Presenilin 1, GAD67, RGS4, GABA-A Rb3) and for examination of the corresponding expression at the protein level.
mRNA expression analysis in rat frontal cortex
Quantification by real-time PCR is shown in Figure 1 . BAD mRNA concentration was not affected by any of the drugs. Haloperidol and clozapine significantly increased the mRNA levels of GAD67 (y4-fold over control), PKCb (6-to 14-fold over control), GABA-A Rb3 (3-fold over control) and PKCc (11-to 19-fold over control). PKCb, GABA-A Rb3 and PKCc were increased significantly also by fluvoxamine (4.8-, 2.8-, and 8-fold over control, respectively). The combined treatment had no statistically significant effects on The levels of fluvoxamine and clozapine were analysed by HPLC (Hartter et al., 1992 ; Weigmann et al., 2001 ) and of haloperidol by tandem mass spectrometry (Zernig et al., 2004) . The values are given as average of six rats (¡S.E.M.) and expressed as drug weight (ng) per wet weight (g) brain tissue. No significant differences were observed in drug concentration between single and combined treatments of haloperidol and fluvoxamine.
any of these genes, although a non-significant increase was noted.
Western blotting analysis of rat frontal cortices
The expression changes at the protein level were examined by immunoblot assay. GAD67 protein level was increased by haloperidol treatment (1.6-fold), reduced by the combined treatment (0.5-fold) and unchanged after fluvoxamine or clozapine (Figure 2a ). PKCb protein was increased by haloperidol (2.6-fold) and by fluvoxamine (1.9-fold) treatments, but reduced by the combination (0.75-fold) (Figure 2c ). GABA-A Rb3 protein level was increased by the haloperidol (1.6-fold) and clozapine treatments (1.9-fold) ( Figure  2b ) and not affected by fluvoxamine alone or in combination with haloperidol. The levels of Cyclin D3, Presenilin 1, RGS4, PKCc and BAD proteins were not Male Sprague-Dawley rats were treated (i.p. injection, 30 d) with haloperidol (Hal, 1.1 mg/kg), fluvoxamine (Flu, 11 mg/kg), a combination of drugs (1 mg/kg and 11 mg/kg respectively), clozapine (Cloz, 11 mg/kg) or vehicle. Hybridization array analysis was performed using Atlas Rat 1.2 cDNA expression arrays, according to the manufacturer's protocol (Clontech). Genes that were affected by the combined treatment in the same direction (up-or down-regulation), in two independent experiments were chosen as a reference point and compared to the results of the other treatments. * 6 rats ; ** 12 rats, n.c., not changed ; Up, ratio >1.5 ; Down, ratio <0.6.
changed with any of the drug treatments (data not shown).
Discussion
The most notable results of the current study are the distinctive protein alterations related to GABA system regulation (GABA-A Rb3, GAD67 and PKCb) following the combined treatment of haloperidol and fluvoxamine. This outcome is not a result of a pharmacokinetic effect on drug metabolism since their concentrations in the brain were similar in the individual and combined treatments. The changes observed at the protein level had limited concordance with those at the mRNA level (haloperidol induction of GAD67, PKCb, GABA-A Rb3 ; no effect of fluvoxamine on GAD67 and increase in PKCb ; increase of GABA-A Rb3 by clozapine and no effect on BAD by any of the treatments). Such disparity has been reported previously (Freeman et al., 2001) and might reflect post-translational processing of the protein. In addition, mRNA changes present in the brain region assayed may be manifested at the protein level only in its projections.
Our findings can be linked to current models of GABA regulation : PKCbII regulates GABA-A receptor function by direct phosphorylation of its b subunits b1, b3 (Brandon et al., 2000 ; Poisbeau et al., 1999 ; Sands et al., 1998 ; Wang et al., 2002) . Treatment with haloperidol modulates PKC via D 2 dopaminergic receptors (Silva et al., 1995 ; Yurko-Mauro and Friedman, 1995) while treatment with fluvoxamine augmentation or clozapine, may regulate PKC via serotonergic receptors (Ago et al., 2005 ; Feng et al., 2001 ; Yan, 2002) , thereby suggesting a potential common pathway for the effect to these drugs. GAD67, another element discussed here, controls the levels of GABA and has been proposed as the key control point linking dopaminergic, glutaminergic (Kalkman and Loetscher, 2003) and serotonergic (Di Cara et al., 2003) systems.
The results of the present study indicate that in the rodent frontal cortex haloperidol may alter GABAergic tone by increasing GAD67 and PKC protein levels. Adding fluvoxamine may oppose the effect of haloperidol.
There are obvious limitations in extrapolating laboratory findings ; however, there is heuristic value in considering possible clinical implications of our study. The alteration in GABAergic elements as seen from fluvoxamine plus haloperidol and its similarity to that following clozapine are of interest in light of evidence for cortical abnormalities of the GABA system in schizophrenia (Blum and Mann, 2002 ; Guidotti et al., 2000 ; Woo et al., 1998) .
The increase in PKCb mRNA and protein levels following the individual fluvoxamine or haloperidol treatments was a novel finding and is complementary to earlier report of elevated PKCb levels in post-mortem brains of schizophrenia patients on antipsychotic drugs (Hakak et al., 2001) , indicating that PKCb changes are related to the treatment. PKCb protein injection, 30 d) with haloperidol (1.1 mg/kg), fluvoxamine (11 mg/kg), a combination of both drugs (1 mg/kg and 11 mg/kg respectively), Clozapine (11 mg/kg) or vehicle. Total RNA isolated from rat frontal cortices was reverse transcribed. cDNA was amplified in real-time PCR using suitable primers for PKCb, PKCc, GABA-A Rb3 GAD67 and BAD (as listed in Table 1 The effect of chronic drug treatments, with haloperidol, fluvoxamine, a combination of both or clozapine on GAD67, GABA-A Rb3 and PKCb protein levels in the rat frontal cortex. Male Sprague-Dawley rats were treated (i.p. injection, 30 d) with haloperidol (1.1 mg/kg), fluvoxamine (11 mg/kg), a combination of both drugs (1 mg/kg and 11 mg/kg respectively), clozapine (11 mg/kg) or vehicle. Protein samples from individual frontal cortices were subjected to Western blot analysis using primary antibodies against GAD67 (a), GABA-A Rb3 (b) and PKCb (c). Immunoreactive bands were analysed by densitometry and normalized against b-actin levels. Percent of control (C) values are given as mean¡S.E.M. of 5-6 rats. Student's t test * p<0.05, ** p<0.01 ; drug group vs. corresponding control group.
impaired learning and working memory in various animal models (Nogues, 1997) . Cognitive impairments and working memory deficit, in particular, are core symptoms of schizophrenia, and are associated with negative symptoms (Silver et al., 2003b ; Strauss, 1993) . This suggests that PKC alterations may be involved in the psychopathology of cognitive and negative symptoms. Indeed, reduced PKC density and transduction have been reported in schizophrenia (Battaini, 2001 ; Dean et al., 1997 ; Pongrac et al., 2002 ; Wang et al., 1999) . The GAD67 protein differences found between haloperidol and clozapine may be a discriminate biomarker between ' typical' and ' atypical ' antipsychotics. The finding that adding fluvoxamine to haloperidol reduced levels of GAD67 suggests a possible relevance of GAD67 protein alteration to negative symptoms improvement. Since fluvoxamine alone did not affect GAD67, the effect on the GABA system may be indirect. Reduced GAD67 levels have been reported in post-mortem brains of schizophrenia patients (Blum and Mann, 2002 ; Guidotti et al., 2000 ; Kalkman and Loetscher, 2003 ; Vawter et al., 2001 ; Volk et al., 2000) and our findings suggest this may be a result of drug effects.
The increase in the level of the b3 subunit of GABA-A receptor by haloperidol and by clozapine is in agreement with results of Sands et al. (1998) and Zink et al. (2004) respectively. Increased GABA-A receptorbinding sites have been reported in chronic schizophrenia patients (Guidotti et al., 2000 ; Hakak et al., 2001) preferentially in the cortex (Benes et al., 1996 ; Blum and Mann, 2002) , a finding usually interpreted as a compensatory up-regulation of post-synaptic receptor sites due to loss of GABAergic neurons (Deutsch et al., 2001) . Taken together with the results of a previous study (Zink et al., 2004) , our findings indicate that these changes may be secondary to drug treatment.
The significance of the finding that the GABA-A subunit was up-regulated following clozapine, but not by the combined haloperidol plus fluvoxamine treatment, is not clear. One possibility is that receptors other than GABA-A (Qin et al., 1994 ; Sands et al., 1998) may be involved in negative symptoms production. In this light, it is of interest that in clinical studies, adding D-cycloserine to clozapine reportedly worsened negative symptoms (Goff et al., 1999) .
It should be noted that while our discussion focused on potential mechanisms underlying treatment response, the possibility that some of the observed changes relate to treatment side-effects (reviewed in Silver, 2003) should also be considered.
In summary, our study indicates that the effects of the combined fluvoxamine plus haloperidol treatment given chronically differ from those of the individual drugs, particularly on the expression of GABA-A receptor modulators. This raises the possibility that alterations in GABAergic components may be involved in the mechanisms underlying the therapeutic effect on negative symptoms in schizophrenia and indicates the need for further study.
